Sandbox/AL: Difference between revisions

Jump to navigation Jump to search
Alejandro Lemor (talk | contribs)
No edit summary
Alejandro Lemor (talk | contribs)
No edit summary
Line 1: Line 1:
{{Family tree/start}}
==Pathogen-Based Therapy — Bacteria <SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from </SMALL></SMALL></SMALL></SMALL></SMALL>==
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF;| | | | | | | | | | | | Z01 | | | | | | | | | Z01=<div style="float: left; text-align: center; width: 15em; padding:1em;"> ❑ '''Immediately order a 12-lead [[ECG|<span style="color:white;">ECG</span>]]'''</div>}}
 
{{familytree | | | | | | | | | | | | |!| | | | | | | | | | }}
<SMALL><font color="#FF4C4C">'''▸ Click on the following categories to expand treatment regimens.'''</font></SMALL>
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF;| | | | | | | | | | | | X01 | | | | | | | | | X01=<div style="text-align: center; width: 15em">'''Does the [[ECG|<span style="color:white;">ECG</span>]] has [[ST elevation|<span style="color:white;">ST elevation</span>]]?''' </div>}}
 
{{familytree | | | | | |,|-|-|-|-|-|-|^|-|-|-|-|-|-|-|.| | | }}
{|
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF;| | | | | B01 | | | | | | | | | | | | | B02 | | | | B01='''YES'''| B02= '''NO''' }}
| valign=top |
{{familytree | | | | | |!| | | | | | | | | | | | | | |!| | | | | | }}
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
{{familytree | |,|-|-|-|+|-|-|-|.| | | |,|-|-|-|v|-|-|^|v|-|-|-|v|-|-|-|.|}}
<font color="#FFF">
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF;| E01 | | E02 | | E03 | | E04 | | E05 | | E06 | | E07 | | E08 | E01=<div style="float: left; text-align: left; width: 12em; padding:1em;">
'''Bacteria'''
'''[[STEMI|<span style="color:white;">STEMI</span>]]''' <br> ❑ Pain described as a heaviness or crushing sensation <br> ❑ Radiates to the left arm, neck and/or jaw <br> ❑ Not alleviated by rest or medications <br>  ❑ PR depression is absent </div>
</font>
| E02=<div style="float: left; text-align: left; width: 12em; padding:1em;">'''New [[LBBB|<span style="color:white;">LBBB</span>]]''' <br> ❑ [[ECG|<span style="color:white;">ECG</span>]] evidence of [[LBBB|<span style="color:white;">LBBB</span>]]
</div>
: ❑ QRS ≥ 120 ms
 
: ❑ QS or rS in V1
<div class="mw-customtoggle-table01" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
: ❑ Monophasic R in I, aVL and V6
<font color="#FFF">
❑ Chest pain with same characteristics as [[STEMI|<span style="color:white;">STEMI</span>]]</div>| E03= <div style="float: left; text-align: left; width: 12em; padding:1em;"> '''[[Pericarditis|<span style="color:white;">Pericarditis</span>]]''' <br> ❑ Sharp and [[pleuritic pain|<span style="color:white;">pleuritic pain</span>]] that is improved by sitting up and leaning forward <br> ❑ Diffuse, non-specific [[ST elevation|<span style="color:white;">ST elevation</span>]] <br> ❑ PR depression  <br> ❑ PR elevation in lead aVR <br><br> '''Suspect [[cardiac tamponade|<span style="color:white;">cardiac tamponade</span>]] when the following finding are present:''' <br> ❑ [[Hypotension|<span style="color:white;">Hypotension</span>]] <br> ❑ [[JVD|<span style="color:white;">JVD</span>]]<br> ❑ [[Muffled heart sounds|<span style="color:white;">Muffled heart sounds</span>]]</div> |E04= <div style="float: left; text-align: left; width: 12em; padding:1em;">'''[[Unstable angina|<span style="color:white;">Unstable angina</span>]]/[[NSTEMI|<span style="color:white;">NSTEMI</span>]]'''<br> ❑ Pain described as a heaviness or crushing sensation <br> ❑ Radiates to the left arm, neck and/or jaw <br> ❑ Not alleviated by rest or medications  <br> ❑ Pain last > 10 min</div> | E05=<div style="float: left; text-align: left; width: 12em; padding:1em;">'''[[Pneumothorax|<span style="color:white;">Pneumothorax</span>]]''' <br> [[Dyspnea|<span style="color:white;">Dyspnea</span>]]<br> ❑ [[Hypoxia|<span style="color:white;">Hypoxia</span>]] <br> ❑  [[Tracheal deviation|<span style="color:white;">Tracheal deviation</span>]] towards the unaffected side<br> ❑ [[percussion|<span style="color:white;">Hyperresonance</span>]] on the affected side  </div> |E06=<div style="float: left; text-align: left; width: 12em; padding:1em;">'''[[Aortic dissection|<span style="color:white;">Aortic dissection</span>]]''' <br> ❑ Acute onset of [[heart failure|<span style="color:white;">heart failure</span>]] <br> ❑ Low pitched early diastolic murmur best heard at the 2nd right [[intercostal space|<span style="color:white;">intercostal space</span>]] <br> ❑ Asymmetric blood pressure in the upper extremities <br> ❑ [[Widened mediastinum|<span style="color:white;">Widened mediastinum</span>]] on [[chest X-ray|<span style="color:white;">chest X-ray</span>]] <br>❑ History of:
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Staphylococcus aureus'''''
: ❑ [[Hypertension|<span style="color:white;">Hypertension</span>]]
</font>
: ❑ [[Marfan syndrome|<span style="color:white;">Marfan syndrome</span>]]</div> | E07=<div style="float: left; text-align: left; width: 12em; padding:1em;">'''[[Pulmonary embolism|<span style="color:white;">Pulmonary embolism</span>]]''' <br> ❑ Sudden onset of [[chest pain|<span style="color:white;">chest pain </span>]] <br> ❑ Severe [[dyspnea|<span style="color:white;">dyspnea</span>]] <br> ❑ History of [[DVT|<span style="color:white;">DVT</span>]], [[surgery|<span style="color:white;">surgery</span>]], [[malignancy|<span style="color:white;">malignancy</span>]], immobility <br>  ❑ Elevated [[D-dimer|<span style="color:white;">D-dimer</span>]]</div> |E08=<div style="float: left; text-align: left; width: 12em; padding:1em;">'''[[Esophageal rupture|<span style="color:white;">Esophageal rupture</span>]]''' <br>  
</div>
❑ Vomiting <br> ❑ Lower chest pain <br> ❑ Cervical [[subcutaneous emphysema|<span style="color:white;">subcutaneous emphysema</span>]] <br> ❑ Overindulgence in alcohol or food <br> ❑ [[chest X-ray|<span style="color:white;">chest X-ray</span>]]
 
: ❑ [[pleural effusion|<span style="color:white;">pleural effusion</span>]]
<div class="mw-customtoggle-table02" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
: ❑ [[pneumothorax|<span style="color:white;">pneumothorax</span>]]
<font color="#FFF">
: ❑ air in the [[mediastium|<span style="color:white;">mediastinum</span>]] or [[peritoneum|<span style="color:white;">peritoneum</span>]] </div>}}
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Staphylococcus epidermidis'''''
{{familytree | |`|-|v|-|'| | | |!| | | |!| | | |!| | | |!| | | |!| | | |!|}}
</font>
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF;| | | E01 | | | | E02 | | E03 | | E04 | | E05 | | E06 | | E07 | E01='''''Key points for management'''''<br>  <div style="float: left; text-align: left; width: 14em; padding:1em;"> '''Administer:'''<br> [[Aspirin|<span style="color:white;">Aspirin</span>]] 162-325 mg <br> ❑ [[Oxygen therapy|<span style="color:white;">Oxygen </span>]](2-4 L/min) if satO2 <90% <br> ❑ [[Beta blockers|<span style="color:white;">Beta blockers</span>]] (unless contraindicated) <br> ❑ Sublingual [[nitroglycerin|<span style="color:white;">nitroglycerin</span>]] 0.4 mg every 5 min for a total of 3 doses <br> '''Do not delay [[primary angioplasty|<span style="color:white;">primary angioplasty</span>]] or [[fibrinolysis|<span style="color:white;">fibrinolysis</span>]]''' <br><br>'''[[STEMI resident survival guide|<span style="color:white;">Click here for the detailed management</span>]]'''</div>| E02='''''Key points for management'''''<br> <div style="float: left; text-align: left; padding:1em;"> ❑ For unstable patients, transfer to [[ICU|<span style="color:white;">ICU</span>]] <br> ❑ In patients with [[cardiac tamponade|<span style="color:white;">cardiac tamponade</span>]] perform [[Pericardiocentesis|<span style="color:white;">pericardiocentesis</span>]] <br><br>'''[[Pericarditis resident survival guide#Treatment of Acute Pericarditis|<span style="color:white;">Click here for the detailed management</span>]]'''</div>|E03 ='''''Key points for management'''''<br>  <div style="float: left; text-align: left; width: 14em; padding:1em;"> '''Administer:'''<br> ❑ [[Aspirin|<span style="color:white;">Aspirin</span>]] 162-325 mg <br> ❑ [[Oxygen therapy|<span style="color:white;">Oxygen </span>]](2-4 L/min) if satO2 <90% <br> ❑ [[Beta blockers|<span style="color:white;">Beta blockers</span>]] (unless contraindicated) <br> ❑ Sublingual [[nitroglycerin|<span style="color:white;">nitroglycerin</span>]] 0.4 mg every 5 min for a total of 3 doses <br> '''Do not delay [[primary angioplasty|<span style="color:white;">primary angioplasty</span>]] or [[fibrinolysis|<span style="color:white;">fibrinolysis</span>]]''' <br><br>'''[[NSTEMI resident survival guide|<span style="color:white;">Click here for the detailed management</span>]]'''</div>| E04='''''Key points for management'''''<br>  <div style="float: left; text-align: left; padding:1em">❑ Immediately [[Tension pneumothorax resident survival guide#Treatment|<span style="color:white;">insert a 14-16 Gauge needle </span>]] in the 2nd [[intercostal space|<span style="color:white;">intercostal space</span>]] at the [[midclavicular line|<span style="color:white;">midclavicular line</span>]] of the affected hemithorax <br><br>'''[[Tension pneumothorax resident survival guide|<span style="color:white;">Click here for the detailed management</span>]]''' </div>|E05='''''Key points for management'''''<br> <div style="float: left; text-align: left; padding:1em">❑ Immediately order a [[TEE|<span style="color:white;">TEE</span>]] to confirm diagnosis<br> ❑ Transfer to a cardio-thoracic unit for surgical management<br><br> '''[[Aortic dissection resident survival guide|<span style="color:white;">Click here for the detailed management</span>]]'''</div> | E06='''''Key points for management'''''<br> <div style="float: left; text-align: left; padding:1em">❑ If the patient is stable, order a [[Pulmonary embolism other imaging findings#Angiography|<span style="color:white;">CT pulmonary angiography</span>]] to confirm diagnosis <br><br> '''[[Pulmonary embolism resident survival guide|<span style="color:white;">Click here for the detailed management</span>]]''' </div>| E07='''''Key points for management'''''<br> <div style="float: left; text-align: left; padding:1em"> ❑ Immediately start antibiotic therapy to prevent [[mediastinitis|<span style="color:white;">mediastinitis</span>]] and [[sepsis|<span style="color:white;">sepsis</span>]] <br> ❑ Surgical repair of the perforation <br><br> '''[[Esophageal rupture resident survival guide|<span style="color:white;">Click here for the detailed management</span>]]'''</div> }}
</div>
{{familytree | | | | | | | | | |`|-|-|-|^|-|v|-|^|-|-|-|^|-|-|-|^|-|-|-|'|}}
 
{{familytree | | | | | | | | | | | | | | | A01 | | | | | A01=<div style="text-align: center; padding: 5px;">'''If none of the above conditions is found, proceed to the [[Chest pain resident survival guide#Complete Diagnostic Approach| complete diagnostic approach]] below'''</div>}}
<div class="mw-customtoggle-table03" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
{{familytree/end}}
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Methicillin-resistant S. aureus'''''
</font>
</div>
 
<div class="mw-customtoggle-table04" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Streptococcus groups A, B, C, G'''''
</font>
</div>
 
<div class="mw-customtoggle-table05" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Enterococcus feacalis'''''
</font>
</div>
 
| valign=top |
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table01" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Staphylococcus aureus''}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Preferred Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Nafcillin]] 2 g IV q6h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Alternative Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]]''''' <br> OR <br> '''''[[Cefazolin]]''''' <br> OR <br> '''''[[Clindamycin]]'''''
|-
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table02" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Staphylococcus epidermidis''}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Preferred Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Vancomycin 15 mg/kg IV q12h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Alternative Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''TMP-SMX'''''<BR> OR <BR>  
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table03" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Methicillin-resistant S. aureus''}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Preferred Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Vancomycin 15 mg/kg IV q12h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Alternative Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''TMP-SMX'''''<BR> OR <BR> '''''[[Doxycycline]]'''' <br> OR <br> '''''[[Linezolid]]'''''
|}
|}{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table21" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Listeria monocytogenes''}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Preferred Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h'''''<BR> OR <BR> ▸ '''''[[Penicillin G]] 4 MU IV q4h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1.7 mg/kg IV q8h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Alternative Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[TMP/SMZ]] 5 mg/kg IV q6—12h''''' <SMALL>(TMP component)</SMALL>
|-
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table22" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''N. meningitidis'', Penicillin MIC <0.1 μg/mL}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Preferred Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] 4 MU IV q4h'''''<BR> OR <BR> ▸ '''''[[Ampicillin]] 2 g IV q4h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Alternative Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q4—6h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''<BR> OR <BR> ▸ '''''[[Chloramphenicol]] 1—1.5 g IV q6h'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''N. meningitidis'', Penicillin MIC ≥0.1 μg/mL}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Preferred Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | '''''[[Cefotaxime]] 2 g IV q4—6h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Alternative Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 2 g IV q8h'''''<BR> OR <BR> '''''[[Chloramphenicol]] 1—1.5 g IV q6h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 400 mg IV q24h'''''<BR> OR <BR> ▸ '''''[[Meropenem]] 2 g IV q8h'''''
|-
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table23" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Pseudomonas aeruginosa''}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Preferred Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftazidime]] 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Cefepime]] 2 g IV q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1.7 mg/kg IV q8h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Alternative Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]] 2 g IV q6—8h'''''<BR> OR <BR> ▸ '''''[[Meropenem]] 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 400 mg IV q8—12h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1.7 mg/kg IV q8h'''''
|-
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table24" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Staphylococcus aureus'', Methicillin sensitive}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Preferred Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Nafcillin]] 1.5—2 g IV q4h'''''<BR> OR <BR> ▸ '''''[[Oxacillin]] 1.5—2 g IV q4h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Alternative Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q6h''''' <SMALL>(trough 15—20 μg/mL)</SMALL><BR> OR <BR> ▸ '''''[[Linezolid]] 600 mg IV q12h'''''<BR> OR <BR> ▸ '''''[[Daptomycin]] 6 mg/kg IV q24h'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Staphylococcus aureus'', Methicillin resistant}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Preferred Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q6h''''' <SMALL>(trough 15—20 μg/mL)</SMALL>
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampin]] 600 mg IV q24h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Alternative Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[TMP/SMZ]] 5 mg/kg IV q6—12h''''' <SMALL>(TMP component)</SMALL><BR> OR <BR> ▸ '''''[[Linezolid]] 600 mg IV q12h'''''<BR> OR <BR> ▸ '''''[[Daptomycin]] 6 mg/kg IV q24h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampin]] 600 mg IV q24h'''''
|-
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table25" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Staphylococcus epidermidis''}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Preferred Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q6h''''' <SMALL>(trough 15—20 μg/mL)</SMALL>
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampin]] 600 mg IV q24h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Alternative Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Linezolid]] 600 mg IV q12h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampin]] 600 mg IV q24h'''''
|-
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table26" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Streptococcus agalactiae''}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Preferred Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h'''''<BR> OR <BR> ▸ '''''[[Penicillin G]] 4 MU IV q4h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1.7 mg/kg IV q8h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Alternative Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q4—6h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''<BR> OR <BR> ▸ '''''[[Vancomycin]] 15 mg/kg IV q6h''''' <SMALL>(trough 15—20 μg/mL)</SMALL>
|-
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table27" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''S. pneumoniae'', Penicillin MIC ≤0.06 μg/mL}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Preferred Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] 4 MU IV q4h'''''<BR> OR <BR> ▸ '''''[[Ampicillin]] 2 g IV q4h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Alternative Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q4—6h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''<BR> OR <BR> ▸ '''''[[Chloramphenicol]] 1—1.5 g IV q6h'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''S. pneumoniae'', Penicillin MIC ≥0.12 μg/mL, Cefotaxime/Ceftriaxone MIC <1.0 μg/mL}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Preferred Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q4—6h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Alternative Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Meropenem]] 2 g IV q8h'''''
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''S. pneumoniae'', Penicillin MIC ≥0.12 μg/mL, Cefotaxime/Ceftriaxone MIC ≥1.0 μg/mL}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Preferred Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q6h''''' <SMALL>(trough 15—20 μg/mL)</SMALL>
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q4—6h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampin]] 600 mg IV q24h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Alternative Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q6h''''' <SMALL>(trough 15—20 μg/mL)</SMALL>
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Moxifloxacin]] 400 mg IV q24h'''''
|-
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table28" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Mycobacterium tuberculosis (New Patients)''}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Intensive Phase'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Isoniazid]] 5 mg/kg PO qd × 2 months'''''<BR> OR <BR> ▸ '''''[[Isoniazid]] 10 mg/kg PO 3 times per week × 2 months'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampicin]] 10 mg/kg PO qd × 2 months'''''<BR> OR <BR> ▸ '''''[[Rifampicin]] 10 mg/kg PO 3 times per week × 2 months'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Pyrazinamide]] 25 mg/kg PO qd × 2 months'''''<BR> OR <BR> ▸ '''''[[Pyrazinamide]] 35 mg/kg PO 3 times per week × 2 months'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Streptomycin]] 15 mg/kg PO qd × 2 months'''''<BR> OR <BR> ▸ '''''[[Streptomycin]] 15 mg/kg PO 3 times per week × 2 months'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Continuation Phase'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Isoniazid]] 5 mg/kg PO qd × 4 months'''''<BR> OR <BR> ▸ '''''[[Isoniazid]] 10 mg/kg PO 3 times per week × 2 months'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampicin]] 10 mg/kg PO qd × 4 months'''''<BR> OR <BR> ▸ '''''[[Rifampicin]] 10 mg/kg PO 3 times per week × 2 months'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL>Adapted from ''Treatment of Tuberculosis: Guidelines.''<ref>{{Cite book  | last1 =  | first1 =  | last2 =  | first2 =  | title = Treatment of tuberculosis : guidelin | date = 2010 | publisher = World Health Organization | location = Geneva | isbn = 978-92-4-154783-3 | pages =  }}</ref></SMALL>
|-
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table29" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center |{{fontcolor|#FFF|''Borrelia burgdorferi''}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Preferred Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 2 g IV q24h × 10—28 days'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Alternative Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q8h × 10—28 days'''''<BR> OR <BR> ▸ '''''[[Penicillin G]] 3—4 MU IV q4h × 10—28 days'''''<BR> OR <BR> ▸ '''''[[Doxycycline]] 100—200 mg PO q12h × 10—28 days'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL>Adapted from ''Clin Infect Dis. 2006;43(9):1089-134.''<ref name="Wormser-2006">{{Cite journal  | last1 = Wormser | first1 = GP. | last2 = Dattwyler | first2 = RJ. | last3 = Shapiro | first3 = ED. | last4 = Halperin | first4 = JJ. | last5 = Steere | first5 = AC. | last6 = Klempner | first6 = MS. | last7 = Krause | first7 = PJ. | last8 = Bakken | first8 = JS. | last9 = Strle | first9 = F. | title = The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. | journal = Clin Infect Dis | volume = 43 | issue = 9 | pages = 1089-134 | month = Nov | year = 2006 | doi = 10.1086/508667 | PMID = 17029130 }}</ref></SMALL>
|-
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table30" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center |{{fontcolor|#FFF|''Treponema pallidum''}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Preferred Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] 3—4 MU IV q4h × 10—14 days'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; text-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" align=center | '''Alternative Regimen'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Procaine penicillin]] 2.4 MU IM q24h × 10—14 days'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Probenecid]] 500 mg PO q6h × 10—14 days'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL>Adapted from ''MMWR Recomm Rep. 2006;55(RR-11):1-94.''<ref name="Workowski-2006">{{Cite journal  | last1 = Workowski | first1 = KA. | last2 = Berman | first2 = SM. | title = Sexually transmitted diseases treatment guidelines, 2006. | journal = MMWR Recomm Rep | volume = 55 | issue = RR-11 | pages = 1-94 | month = Aug | year = 2006 | doi =  | PMID = 16888612 }}</ref></SMALL>
|-
|}
|}
|}

Revision as of 18:11, 15 May 2014

Pathogen-Based Therapy — Bacteria Adapted from

▸ Click on the following categories to expand treatment regimens.

Bacteria

  ▸  Staphylococcus aureus

  ▸  Staphylococcus epidermidis

  ▸  Methicillin-resistant S. aureus

  ▸  Streptococcus groups A, B, C, G

  ▸  Enterococcus feacalis

Staphylococcus aureus
Preferred Regimen
Nafcillin 2 g IV q6h
Alternative Regimen
Vancomycin
OR
Cefazolin
OR
Clindamycin
Staphylococcus epidermidis
Preferred Regimen
Vancomycin 15 mg/kg IV q12h
Alternative Regimen
TMP-SMX
OR
Methicillin-resistant S. aureus
Preferred Regimen
Vancomycin 15 mg/kg IV q12h
Alternative Regimen
TMP-SMX
OR
Doxycycline'
OR
Linezolid
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table21" style="background: #FFFFFF;"
Listeria monocytogenes
Preferred Regimen
Ampicillin 2 g IV q4h
OR
Penicillin G 4 MU IV q4h
PLUS
Gentamicin 1.7 mg/kg IV q8h
Alternative Regimen
TMP/SMZ 5 mg/kg IV q6—12h (TMP component)
N. meningitidis, Penicillin MIC <0.1 μg/mL
Preferred Regimen
Penicillin G 4 MU IV q4h
OR
Ampicillin 2 g IV q4h
Alternative Regimen
Cefotaxime 2 g IV q4—6h
OR
Ceftriaxone 2 g IV q12h
OR
Chloramphenicol 1—1.5 g IV q6h
N. meningitidis, Penicillin MIC ≥0.1 μg/mL
Preferred Regimen
Cefotaxime 2 g IV q4—6h
OR
Ceftriaxone 2 g IV q12h
Alternative Regimen
Cefepime 2 g IV q8h
OR
Chloramphenicol 1—1.5 g IV q6h
OR
Moxifloxacin 400 mg IV q24h
OR
Meropenem 2 g IV q8h
Pseudomonas aeruginosa
Preferred Regimen
Ceftazidime 2 g IV q8h
OR
Cefepime 2 g IV q8h
PLUS
Gentamicin 1.7 mg/kg IV q8h
Alternative Regimen
Aztreonam 2 g IV q6—8h
OR
Meropenem 2 g IV q8h
OR
Ciprofloxacin 400 mg IV q8—12h
PLUS
Gentamicin 1.7 mg/kg IV q8h
Staphylococcus aureus, Methicillin sensitive
Preferred Regimen
Nafcillin 1.5—2 g IV q4h
OR
Oxacillin 1.5—2 g IV q4h
Alternative Regimen
Vancomycin 15 mg/kg IV q6h (trough 15—20 μg/mL)
OR
Linezolid 600 mg IV q12h
OR
Daptomycin 6 mg/kg IV q24h
Staphylococcus aureus, Methicillin resistant
Preferred Regimen
Vancomycin 15 mg/kg IV q6h (trough 15—20 μg/mL)
PLUS
Rifampin 600 mg IV q24h
Alternative Regimen
TMP/SMZ 5 mg/kg IV q6—12h (TMP component)
OR
Linezolid 600 mg IV q12h
OR
Daptomycin 6 mg/kg IV q24h
PLUS
Rifampin 600 mg IV q24h
Staphylococcus epidermidis
Preferred Regimen
Vancomycin 15 mg/kg IV q6h (trough 15—20 μg/mL)
PLUS
Rifampin 600 mg IV q24h
Alternative Regimen
Linezolid 600 mg IV q12h
PLUS
Rifampin 600 mg IV q24h
Streptococcus agalactiae
Preferred Regimen
Ampicillin 2 g IV q4h
OR
Penicillin G 4 MU IV q4h
PLUS
Gentamicin 1.7 mg/kg IV q8h
Alternative Regimen
Cefotaxime 2 g IV q4—6h
OR
Ceftriaxone 2 g IV q12h
OR
Vancomycin 15 mg/kg IV q6h (trough 15—20 μg/mL)
S. pneumoniae, Penicillin MIC ≤0.06 μg/mL
Preferred Regimen
Penicillin G 4 MU IV q4h
OR
Ampicillin 2 g IV q4h
Alternative Regimen
Cefotaxime 2 g IV q4—6h
OR
Ceftriaxone 2 g IV q12h
OR
Chloramphenicol 1—1.5 g IV q6h
S. pneumoniae, Penicillin MIC ≥0.12 μg/mL, Cefotaxime/Ceftriaxone MIC <1.0 μg/mL
Preferred Regimen
Cefotaxime 2 g IV q4—6h
OR
Ceftriaxone 2 g IV q12h
Alternative Regimen
Cefepime 2 g IV q8h
OR
Meropenem 2 g IV q8h
S. pneumoniae, Penicillin MIC ≥0.12 μg/mL, Cefotaxime/Ceftriaxone MIC ≥1.0 μg/mL
Preferred Regimen
Vancomycin 15 mg/kg IV q6h (trough 15—20 μg/mL)
PLUS
Cefotaxime 2 g IV q4—6h
OR
Ceftriaxone 2 g IV q12h
PLUS
Rifampin 600 mg IV q24h
Alternative Regimen
Vancomycin 15 mg/kg IV q6h (trough 15—20 μg/mL)
PLUS
Moxifloxacin 400 mg IV q24h
Mycobacterium tuberculosis (New Patients)
Intensive Phase
Isoniazid 5 mg/kg PO qd × 2 months
OR
Isoniazid 10 mg/kg PO 3 times per week × 2 months
PLUS
Rifampicin 10 mg/kg PO qd × 2 months
OR
Rifampicin 10 mg/kg PO 3 times per week × 2 months
PLUS
Pyrazinamide 25 mg/kg PO qd × 2 months
OR
Pyrazinamide 35 mg/kg PO 3 times per week × 2 months
PLUS
Streptomycin 15 mg/kg PO qd × 2 months
OR
Streptomycin 15 mg/kg PO 3 times per week × 2 months
Continuation Phase
Isoniazid 5 mg/kg PO qd × 4 months
OR
Isoniazid 10 mg/kg PO 3 times per week × 2 months
PLUS
Rifampicin 10 mg/kg PO qd × 4 months
OR
Rifampicin 10 mg/kg PO 3 times per week × 2 months
Adapted from Treatment of Tuberculosis: Guidelines.[1]
Borrelia burgdorferi
Preferred Regimen
Ceftriaxone 2 g IV q24h × 10—28 days
Alternative Regimen
Cefotaxime 2 g IV q8h × 10—28 days
OR
Penicillin G 3—4 MU IV q4h × 10—28 days
OR
Doxycycline 100—200 mg PO q12h × 10—28 days
Adapted from Clin Infect Dis. 2006;43(9):1089-134.[2]
Treponema pallidum
Preferred Regimen
Penicillin G 3—4 MU IV q4h × 10—14 days
Alternative Regimen
Procaine penicillin 2.4 MU IM q24h × 10—14 days
PLUS
Probenecid 500 mg PO q6h × 10—14 days
Adapted from MMWR Recomm Rep. 2006;55(RR-11):1-94.[3]

|}

  1. Treatment of tuberculosis : guidelin. Geneva: World Health Organization. 2010. ISBN 978-92-4-154783-3.
  2. Wormser, GP.; Dattwyler, RJ.; Shapiro, ED.; Halperin, JJ.; Steere, AC.; Klempner, MS.; Krause, PJ.; Bakken, JS.; Strle, F. (2006). "The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America". Clin Infect Dis. 43 (9): 1089–134. doi:10.1086/508667. PMID 17029130. Unknown parameter |month= ignored (help)
  3. Workowski, KA.; Berman, SM. (2006). "Sexually transmitted diseases treatment guidelines, 2006". MMWR Recomm Rep. 55 (RR-11): 1–94. PMID 16888612. Unknown parameter |month= ignored (help)